Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00224523
Status:
COMPLETED
Last Update Posted:
2016-10-28
First Post:
2005-08-26
Brief Title:
Long Term Safety Of GW685698X Via Nasal Biopsy
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Open Label Active Controlled Mometasone Furoate Aqueous Nasal Spray Nasonex 200mcg QD Parallel Group Multi-Center 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD Via Nasal Biopsy in Subjects 18 Years of Age With Perennial Allergic Rhinitis PAR
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Long term safety 52 weeks of GW685698X on the nasal mucosa via nasal biopsy with an active control group Nasonex and a healthy volunteers control group in subjects 18 years old with perennial allergic rhinitis Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure Perennial allergic rhinitis is triggered by house dust mites animal dander etc possibly causing symptoms year-round including nasal congestion rhinorrhea andor nasal itching
Detailed Description:
A Randomized Open Label Active Controlled Mometasone Furoate Aqueous Nasal Spray Nasonex 200mcg QD Parallel Group Multi-Center 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD via Nasal Biopsy in Subjects 18 Years of Age with Perennial Allergic Rhinitis PAR
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None